Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

Article Details

Citation

Copy to clipboard

Lebovitz HE

Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:142-7.

PubMed ID

16627399 [ View in PubMed

]

Abstract

OBJECTIVE: To review new pharmacologic therapies and technologies relevant to the management of diabetes and its complications. METHODS: New treatment options for diabetes, made available through research efforts during the past 2 decades, are discussed. RESULTS: Several new drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and tesaglitazar, the inhaled insulin preparation Exubera, and the insulin analogues (insulin glulisine and insulin detemir). CONCLUSION: New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Many other agents that act on fundamental abnormalities such as energy imbalance, inflammation, and vascular biologic conditions are in very early stages of development but are likely to become available during the next 5 to 10 years.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Exenatide	Glucagon-like peptide 1 receptor	Protein	Humans	Yes	Agonist	Details